Special Issue "Redox Signaling at the Crossroads of Immunity, Inflammation, Infectious Disease, and Cancer"

A special issue of Antioxidants (ISSN 2076-3921).

Deadline for manuscript submissions: 31 January 2022.

Special Issue Editors

Dr. Debasis Mondal
E-Mail Website
Guest Editor
Associate Professor of Microbiology, Lincoln Memorial University—Debusk College of Osteopathic Medicine, 9737 Cogdill Road, Knoxville, TN 37932, USA
Interests: microbiology; oncology; therapeutics
Special Issues, Collections and Topics in MDPI journals
Dr. Syed Siraj A. Quadri
E-Mail
Guest Editor
Associate Professor of Pharmacology, Lincoln Memorial University—Debusk College of Osteopathic Medicine, 9737 Cogdill Road, Knoxville, TN 37932, USA
Interests: pharmacology; cardiovascular disease; therapy
Special Issues, Collections and Topics in MDPI journals

Special Issue Information

Dear Colleague,

Reactive oxygen species (ROS) manifest effects that encompass both beneficial physiological functions as well as damaging alterations of cellular components. These two opposing effects of ROS seem to depend on the amount, location, duration, and types of ROS that are generated within the cell. Indeed, normal functioning of the immune system, both innate and adaptive mechanisms, involve acute ROS production and intricately regulated redox signaling. A dysfunctional immune system resulting from oxidative stress and chronic inflammation are now known to be responsible for the initiation, progression, and therapeutic resistance of numerous diseases. However, despite decades of research in this field, no effective therapy is currently approved for regulating altered redox signaling at the crossroads of immunity, inflammation, infectious diseases, and cancer. This Special Issue of Antioxidants will focus on the mechanisms linked to the regulation of pro- and antioxidants in both normal and pathological circumstances. In addition, this Special Issue will address druggable targets that show promise in clinical settings. Therefore, basic research, clinical case reports, as well as review articles will be accepted.

Dr. Debasis Mondal
Dr. Syed Siraj A. Quadri
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All papers will be peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Antioxidants is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2000 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • Chronic diseases
  • Inflammation
  • Redox signaling
  • Oxidative stress
  • Autophagy
  • Therapy
  • Side effects
  • Phytochemicals
  • Pharmaceuticals
  • Microbiome
  • Exosome

Published Papers (1 paper)

Order results
Result details
Select all
Export citation of selected articles as:

Review

Review
Statins’ Regulation of the Virulence Factors of Helicobacter pylori and the Production of ROS May Inhibit the Development of Gastric Cancer
Antioxidants 2021, 10(8), 1293; https://0-doi-org.brum.beds.ac.uk/10.3390/antiox10081293 - 16 Aug 2021
Viewed by 660
Abstract
Conventionally, statins are used to treat high cholesterol levels. They exhibit pleiotropic effects, such as the prevention of cardiovascular disease and decreased cancer mortality. Gastric cancer (GC) is one of the most common cancers, ranking as the third leading global cause of cancer-related [...] Read more.
Conventionally, statins are used to treat high cholesterol levels. They exhibit pleiotropic effects, such as the prevention of cardiovascular disease and decreased cancer mortality. Gastric cancer (GC) is one of the most common cancers, ranking as the third leading global cause of cancer-related deaths, and is mainly attributed to chronic Helicobacter pylori infection. During their co-evolution with hosts, H. pylori has developed the ability to use the cellular components of the host to evade the immune system and multiply in intracellular niches. Certain H. pylori virulence factors, including cytotoxin-associated gene A (CagA), vacuolating cytotoxin A (VacA), and cholesterol-α-glucosyltransferase (CGT), have been shown to exploit host cholesterol during pathogenesis. Therefore, using statins to antagonize cholesterol synthesis might prove to be an ideal strategy for reducing the occurrence of H. pylori-related GC. This review discusses the current understanding of the interplay of H. pylori virulence factors with cholesterol and reactive oxygen species (ROS) production, which may prove to be novel therapeutic targets for the development of effective treatment strategies against H. pylori-associated GC. We also summarize the findings of several clinical studies on the association between statin therapy and the development of GC, especially in terms of cancer risk and mortality. Full article
Show Figures

Graphical abstract

Back to TopTop